Jamesm Daly News Today

Paulson & CO. Inc. increased its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 121.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,105,741 shares of the biopharmaceutical company’s stock after purchasing an additional 605,741 shares during the quarter. Madrigal […]

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to […]

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($6.06) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link. Madrigal Pharmaceuticals […]

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) fell 3.3% during mid-day trading on Wednesday . The company traded as low as $225.22 and last traded at $225.22. 43,731 shares were traded during trading, a decline of 92% from the average session volume of 525,723 shares. The stock had previously closed at $232.98. […]

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY23 earnings guidance on Monday. The company provided earnings per share guidance of $2.70-$2.80 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $825-$845 million, compared to the consensus revenue estimate of $830.22 million. Halozyme Therapeutics […]

Benchmark reissued their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a research note issued to investors on Friday, Benzinga reports. Benchmark currently has a $50.00 target price on the biopharmaceutical company’s stock. HALO has been the topic of several other research reports. The Goldman Sachs Group downgraded Halozyme Therapeutics from […]

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director James M. Daly sold 10,000 shares of the company’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $43.74, for a total value of $437,400.00. Following the completion of the sale, the director now owns 20,503 shares of […]

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. Several other equities research analysts have also commented on the stock. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $46.00 […]